RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Solasia Pharma of Japan announced progress in China for two of its products that treat chemotherapy side effects: episil ® oral liquid, a treatment for chemotherapy-induced oral mucosa, was approved for China use, and Sancuso, a transdermal Granisetron patch, was approved for China launch as a treatment for chemotherapy-related nausea and vomiting. episil® is a pocket-sized spray that allows patients to manage oral mucosa side effects. Sancuso, a 5-HT3 antagonist transdermal patch, offers chemotherapy patients a noninvasive treatment for nausea and vomiting. Solasia will distribute the two products in Shanghai, Beijing and Guangzhou; Lee’s Pharma will distribute them elsewhere in China.
Source: China Biotoday
